A discovery about the brain may offer new hope to smokers finding it hard to quit. Scientists writing in the journal Nature Communications describe how they identified circuits in the brain that they believe are responsible for the anxiety that often accompanies nicotine withdrawal.
Senior author Andrew Tapper, associate professor of psychiatry at the University of Massachusetts Medical School (UMMS), says:
“Increased anxiety is a prominent nicotine withdrawal symptom that contributes to relapse in smokers attempting to quit.”
He and his colleagues found circuitry in the brain that appears to be specifically wired to increase anxiety during nicotine withdrawal.
The team also discovered several other interconnected features in the brain that trigger anxiety during nicotine withdrawal.
They suggest their findings may open the door to new treatments to relieve or even prevent anxiety during nicotine withdrawal.
The new work builds on achievements accomplished over several years – both at UMMS and at The Scripps Research Institute in La Jolla, CA.
It follows, for example, a study published in 2013 in the journal Current Biology, where Prof. Tapper and colleagues had shown that a specific set of cells in a region of the brain known as the interpeduncular nucleus causes physical nicotine withdrawal symptoms, such as headaches, nausea and insomnia originate.
The team was surprised to find that the area of the interpeduncular nucleus that is activated during withdrawal-related anxiety is distinct from the sub-region they had previously identified as being linked to nicotine withdrawal behaviors.
The researchers were also surprised to find that signals from two other brain regions come together at the interpeduncular nucleus to trigger anxiety-causing brain cells.
One of the signals comes from the ventral tegmental area – a group of cells at the very centre of the brain – which is normally linked with reward or pleasure. The study shows that this area activates brain cells in the interpeduncular nucleus using corticotropin releasing factor (CRF) – a brain chemical that is released in response to stress.
The other signal comes from the medial habenula and triggers cells in the interpeduncular nucleus by releasing glutamate – the chemical most used by brain cells to send signals to each other. In this case, the arrival of CRF at the interpeduncular nucleus cells appears to increase the effect of glutamate.
In further tests, the researchers found they could alleviate anxiety in mice by reducing the stimulation of the cells in the interpeduncular nucleus, and they suggest the same may be possible in humans.
Prof. Tapper says both of the inputs – CRF from the ventral tegmental area, and glutamate from the medial habenula – appear to be important and offer potential treatment targets:
“We could alleviate anxiety during nicotine withdrawal by either preventing corticotropin releasing factor synthesis in the ventral tegmental area, or by silencing the medial habenula inputs into the interpeduncular nucleus.”
Drugs that block CRF receptors on cells already exist, says Prof. Tapper. He also notes that these receptors have already been linked to anxiety and depression, so their study findings could have implications for anxiety disorders in general.
The team now plans to investigate interactions between anxiety, stress, reward and withdrawal from addictive substances and explore whether the circuits they have identified relate to stress-induced anxiety in general or just that induced by nicotine withdrawal.
In September 2014, Medical News Today learned how researchers found that nicotine withdrawal reduced reward responsiveness and the effect was particularly strong in smokers with a history of depression.